Is Lunai Bioworks Inc. (LNAI) Halal?

NASDAQ Healthcare United States $10M
✗ NOT HALAL
Confidence: 90/100
Lunai Bioworks Inc. (LNAI) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 181.1% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. Lunai Bioworks Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from June 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 181.1%
/ 30%
8.6%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 181.1%
/ 33%
8.6%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 123.6%
/ 33%
5.8%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 181.1%
/ 33%
8.6%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 123.6%
/ 33%
5.8%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-7.56
P/B Ratio
-0.7
EV/EBITDA
-1.0
EV: $12M
Revenue
$0
Beta
0.6
Low volatility
Current Ratio
0.0

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -366.4%
Return on Assets (ROA) -13.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$8M
Free Cash Flow-$8M
Total Debt$10M
Current Ratio0.0
Total Assets$8M

Price & Trading

Last Close$0.49
50-Day MA$0.57
200-Day MA$1.54
Avg Volume12.0M
Beta0.6
52-Week Range
$0.15
$6.12

About Lunai Bioworks Inc. (LNAI)

CEO
Mr. David H. Weinstein
Employees
29
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$10M
Currency
USD

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Lunai Bioworks Inc. (LNAI) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Lunai Bioworks Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Lunai Bioworks Inc.'s debt ratio?

Lunai Bioworks Inc.'s debt ratio is 181.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 123.6%.

What are Lunai Bioworks Inc.'s key financial metrics?

Lunai Bioworks Inc. has a market capitalization of $10M. Return on equity stands at -366.4%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.